Telomerase Reverse Transcriptase Market By Type (ASTVAC-1, ASTVAC-2, ETS-2300, and Others), By Application (Lung Cancer, Breast Cancer, Ovarian Cancer, and Others), Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2023-2030

Market Definition

Telomerase reverse transcriptase (TERT) is a catalytic subunit of the enzyme telomerase, together with the telomerase RNA component.

Telomerase reverse transcriptase has been a useful therapeutic target in different studies of cancer.

Market Dynamics

The increasing incidence of cancer is the key driving factor of the market. For instance, according to the American Institute for Cancer Research, breast cancer is the second most common cancer globally. According to the World Health Organization (WHO), globally, lung cancer accounts for 2.09 million cases in 2018. According to the American Cancer Society, in 2020, an estimated 228,820 new cases of lung cancer was diagnosed in the United States. According to the World Health Organization (WHO), every year, around 900,000 people worldwide are diagnosed with blood cancer. Globally, around 2 million new cases of breast cancer are diagnosed in 2018. Around 627,000 women died from breast cancer, which is approximately 15% of all cancer deaths among women in 2018. According to the World Health Organization (WHO), globally, colorectal cancer accounts for 1.80 million cases in 2018. According to the American Cancer Society’s (ACS), in 2020, an estimate of 147,950 adults in the United States are expected to diagnose with colorectal cancer. According to the American Cancer Society, it is estimated that in 2020 there will be 191,930 new cases of prostate cancer and 33,330 deaths from prostate cancer in the United States. However, the side effect of telomerase reverse transcriptase might hamper the market growth. Some of the adverse effects of telomerase reverse transcriptase include low blood platelet and neutrophil count, diabetes mellitus, bone pain, injection site reactions, redness of the skin, and vitiligo. Moreover, increasing clinical studies on telomerase reverse transcriptase would provide lucrative opportunities for the market in the coming years.

Market Segmentation

The global telomerase reverse transcriptase market is mainly classified based on type and application. Type is further segmented into ASTVAC-1, ASTVAC-2, ETS-2300, and Others. By application, the market is divided into Lung Cancer, Breast Cancer, Ovarian Cancer, and Others.

ASTVAC-2 might show significant growth in the coming years, owing to the collaboration between companies to develop ASTVAC-2 cancer vaccine and increasing clinical studies on ASTVAC-2 for cancer treatment. For instance, Asterias Biotherapeutics, Inc., a biotechnology company developing cellular immunotherapies to treat cancer and cell-based therapeutics for the treatment of neurological conditions associated with demyelination, has conducted Phase 1 clinical trial of AST-VAC2 in the United Kingdom. This clinical trial is sponsored, managed, and funded by Cancer Research UK and will examine the safety and tolerability of AST-VAC2 in non-small cell lung cancer. The study includes evaluations of the immunogenicity of AST-VAC2 in non-small cell lung cancer.

Regional Analysis

Based on geography, the global telomerase reverse transcriptase market is divided into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America is further divided in the U.S., Canada, and Mexico, whereas Europe consists of the UK, Germany, France, Italy, and Rest of Europe. Asia-Pacific is segmented into India, China, Japan, South Korea, and Rest of Asia-Pacific. The South America region includes Brazil, Argentina, and the Rest of South America, while the Middle East & Africa is categorized into GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa.

North America is expected to dominate the telomerase reverse transcriptase market in the coming years, due to the rising prevalence of cancer. According to the American Cancer Society, in 2020, an estimated 1.8 million new cancer cases will be diagnosed and 606,520 cancer deaths in the United States. Moreover, rising clinical studies for cancer treatment and increasing investment by companies and government organizations for the treatment of cancer are some of the factors that are boosting the North America telomerase reverse transcriptase market.

Competitive landscape

Major players operating in the telomerase reverse transcriptase industry include F. Hoffmann-La Roche Ltd, Asterias Biotherapeutics Inc, Johnson & Johnson, Inovio Pharmaceuticals Inc, e-Therapeutics Plc, Invectys SA, Komipharm International Co Ltd, Telocyte LLC, Mediolanum farmaceutici SpA, Argos Therapeutics Inc, Vaxon Biotech, TILT Biotherapeutics Ltd, and Ultimovacs AS.

The companies are increasing the development of telomerase reverse transcriptase for the treatment of cancer, increasing clinical trials for telomerase reverse transcriptase and companies are jointly researching telomerase reverse transcriptase for the treatment of cancer are some of the strategies adopted by the major companies. For instance, on September 9, 2019, Personalis, Inc. has entered into a research agreement with Invectys, the company focused on the development of immunotherapy to treat cancers. Based on the agreement, Personalis will provide comprehensive tumor immunogenomics capabilities to facilitate biomarker discovery in chronic lymphocytic leukemia (CLL) patients that are enrolled in Phase II clinical trial assessing the efficacy of INVAC-1, a modified human telomerase reverse transcriptase (hTERT) protein, in combination with ibrutinib.

Telomerase Reverse Transcriptase Market Key Segments:

By Type
• ASTVAC-1
• ASTVAC-2
• ETS-2300
• Others

By Application
• Lung Cancer
• Breast Cancer
• Ovarian Cancer
• Others

Key Global Telomerase Reverse Transcriptase Industry Players
• F. Hoffmann-La Roche Ltd
• Asterias Biotherapeutics Inc
• Johnson & Johnson
• Inovio Pharmaceuticals Inc
• e-Therapeutics Plc
• Invectys SA
• Komipharm International Co Ltd
• Telocyte LLC
• Mediolanum farmaceutici SpA
• Argos Therapeutics Inc
• Vaxon Biotech
• TILT Biotherapeutics Ltd
• Ultimovacs AS

Table of Content

1. Market Introduction
1.1. Executive Summary
1.2. Market Definition
1.3. Market Scope

2. Research Methodology
2.1. Primary Research
2.2. Research Methodology
2.3. Assumptions & Exclusions
2.4. Secondary data sources

3. Telomerase Reverse Transcriptase Market Overview
3.1. Report Segmentation & Scope
3.2. Key Market Trend
3.3. Drivers
3.3.1. Rising Prevalence of Cancer
3.4. Restraints
3.4.1. Side Effect of Telomerase Reverse Transcriptase
3.5. Opportunity
3.5.1. Increasing Clinical Studies on Telomerase Reverse Transcriptase
3.6. Porter’s Five Forces Analysis
3.6.1. Porter’s Five Forces Analysis
3.7. Market Share Analysis

4. Type Overview
4.1. Introduction
4.1.1. Market Size & Forecast
4.2. ASTVAC-1
4.2.1. Market Size & Forecast
4.3. ASTVAC-2
4.3.1. Market Size & Forecast
4.4. ETS-2300
4.4.1. Market Size & Forecast
4.5. Others
4.5.1. Market Size & Forecast

5. Application Overview
5.1. Introduction
5.1.1. Market Size & Forecast
5.2. Lung Cancer
5.2.1. Market Size & Forecast
5.3. Breast Cancer
5.3.1. Market Size & Forecast
5.4. Ovarian Cancer
5.4.1. Market Size & Forecast
5.5. Others
5.5.1. Market Size & Forecast

6. Telomerase Reverse Transcriptase Market Regional Overview
6.1. Introduction
6.1.1. Market Size & Forecast
6.2. North America Telomerase Reverse Transcriptase Market
6.2.1. North America Market Size & Forecast, By Country
6.2.2. North America Market Size & Forecast, By Type
6.2.3. North America Market Size & Forecast, By Application
6.2.4. U.S.
6.2.4.1. Market Size and Forecast
6.2.5. Canada
6.2.5.1. Market Size and Forecast
6.2.6. Mexico
6.2.6.1. Market Size and Forecast
6.3. Europe Telomerase Reverse Transcriptase Market
6.3.1. Europe Market Size & Forecast, By Country
6.3.2. Europe Market Size & Forecast, By Type
6.3.3. Europe Market Size & Forecast, By Application
6.3.4. Germany
6.3.4.1. Market Size and Forecast
6.3.5. France
6.3.5.1. Market Size and Forecast
6.3.6. UK
6.3.6.1. Market Size and Forecast
6.3.7. Italy
6.3.7.1. Market Size and Forecast
6.3.8. Spain
6.3.8.1. Market Size and Forecast
6.3.9. Rest of Europe
6.3.9.1. Market Size and Forecast
6.4. Asia-Pacific Telomerase Reverse Transcriptase Market
6.4.1. Asia-Pacific Market Size & Forecast, By Country
6.4.2. Asia-Pacific Market Size & Forecast, By Type
6.4.3. Asia-Pacific Market Size & Forecast, By Application
6.4.4. Japan
6.4.4.1. Market Size and Forecast
6.4.5. China
6.4.5.1. Market Size and Forecast
6.4.6. Australia
6.4.6.1. Market Size and Forecast
6.4.7. India
6.4.7.1. Market Size and Forecast
6.4.8. South Korea
6.4.8.1. Market Size and Forecast
6.4.9. Rest of Asia-Pacific
6.4.9.1. Market Size and Forecast
6.5. South America Telomerase Reverse Transcriptase Market
6.5.1. South America Market Size & Forecast, By Country
6.5.2. South America Market Size & Forecast, By Type
6.5.3. South America Market Size & Forecast, By Application
6.5.4. Brazil
6.5.4.1. Market Size and Forecast
6.5.5. Argentina
6.5.5.1. Market Size and Forecast
6.5.6. Rest of South America
6.5.6.1. Market Size and Forecast
6.6. Middle East & Africa Telomerase Reverse Transcriptase Market
6.6.1. Middle East & Africa Market Size & Forecast, By Country
6.6.2. Middle East & Africa Market Size & Forecast, By Type
6.6.3. Middle East & Africa Market Size & Forecast, By Application
6.6.4. GCC Countries
6.6.4.1. Market Size and Forecast
6.6.5. Egypt
6.6.5.1. Market Size and Forecast
6.6.6. South Africa
6.6.6.1. Market Size and Forecast
6.6.7. Rest of Middle East & Africa
6.6.7.1. Market Size and Forecast

7. Company Profile
7.1. F. Hoffmann-La Roche Ltd
7.1.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.1.2. F. Hoffmann-La Roche Ltd Product Category, Application, and Specification
7.1.3. F. Hoffmann-La Roche Ltd Financial Performance (2016-2018)
7.1.4. Main Business/Business Overview
7.2. Asterias Biotherapeutics Inc
7.3. Johnson & Johnson
7.4. Inovio Pharmaceuticals Inc
7.5. e-Therapeutics Plc
7.6. Invectys SA
7.7. Komipharm International Co Ltd
7.8. Telocyte LLC
7.9. Mediolanum farmaceutici SpA
7.10. Argos Therapeutics Inc
7.11. Vaxon Biotech
7.12. TILT Biotherapeutics Ltd
7.13. Ultimovacs AS